# EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE
> **ANDA091215** · Abbreviated New Drug Application (Generic) · Sponsor: TEVA PHARMS USA · Approved 2018-11-09
## Drug
- **FDA Application Number:** ANDA091215
- **Application type:** Abbreviated New Drug Application (Generic)
- **Brand name:** EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE
- **Generic name:** EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE
- **Active ingredients:** EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
- **Dosage form:** TABLET
- **Route:** ORAL
- **Marketing status:** Prescription
- **Sponsor:** TEVA PHARMS USA
- **Manufacturer:** Teva Pharmaceuticals USA, Inc.
- **First approval:** 2018-11-09
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=091215)
---
*MORVS · CC0 1.0*